After decades of additional research, azacitidine (Vidaza) was approved by the Food and Drug Administration in 2004 for
treating myelodysplastic syndrome (MDS), a cancer of the blood and bone marrow.
Currently, researchers are studying arsenic trioxide, as a single agent or in combination with other medicines, for
treating myelodysplastic syndromes.
Azacitidine is approved by the U.S. Food and Drug Administration (FDA) for
treating all myelodysplastic syndromes (MDS) subtypes.
Decitabine is approved by the U.S. Food and Drug Administration to
treat myelodysplastic syndromes and leukemia, and for use in clinical trials for several types of solid - tumour cancers including colorectal.
Not exact matches
The researchers
treated 63 cancer cell lines (26 breast, 14 colorectal and 23 ovarian) with low - dose 5 - azacitidine (AZA), an FDA - approved drug for
myelodysplastic syndrome, that reverses epigenetic changes by stripping off the methyl group that silences the gene.
Inclusion Criteria: • Subject has a diagnosis of primary acute myeloid leukemia (AML) or AML secondary to
myelodysplastic syndrome (MDS) according to WHO classification (2008) as determined by pathology review at the
treating institute.
It is approved for
treating low - risk, transfusion - dependent
myelodysplastic syndrome (MDS) patients with an abnormality of chromosome 5q.
Emergence and evolution of TP53 mutations are key features of disease progression in
myelodysplastic patients with lower - risk del (5q)
treated with lenalidomide